• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Travere Therapeutics Inc (NQ: TVTX )

    17.66 +0.36 (+2.08%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Travere Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 Next >
    A Preview Of Travere Therapeutics's Earnings
    Via Benzinga
    Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
    Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker. 
    Via Benzinga
    Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
    Via Benzinga
    Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
    Via Benzinga
    Where Travere Therapeutics Stands With Analysts
    Via Benzinga
    Analyst Ratings For Travere Therapeutics
    Via Benzinga
    Expert Ratings For Travere Therapeutics
    Via Benzinga
    Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
    The company could soon ask for approval of its only drug, Filspari, in a second disease. 
    Via Investor's Business Daily
    Exposures Product Safety
    Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
    Via Benzinga
    Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
    Via Benzinga
    Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
    Via Benzinga
    Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
    The company previously had an accelerated approval for its IgA nephropathy treatment. 
    Via Investor's Business Daily
    NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
    Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
    Via Talk Markets
    Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)
    Via Benzinga
    Earnings Scheduled For February 15, 2024
    Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
    Via Benzinga
    Earnings Preview For Travere Therapeutics
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024
    TVTX stock results show that Travere Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
    The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
    Via Benzinga
    Exposures Product Safety
    Where Travere Therapeutics Stands With Analysts
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.